The Galleri multi-cancer early detection test is not FDA approved. It is currently available as a laboratory-developed test (LDT), which means it can be ordered by physicians but has not undergone formal FDA review and clearance. GRAIL, the company behind Galleri, submitted the final module of its Premarket Approval (PMA) application to the FDA in January 2026, so a decision could come within the next one to two years.
How Galleri Is Available Without FDA Approval
Laboratory-developed tests occupy a unique regulatory space in the U.S. They are created and performed within a single laboratory, and historically the FDA has exercised limited oversight over them. This is the pathway Galleri currently uses to reach patients. You can get the test through a physician’s order, but it has not been evaluated by the FDA for safety or effectiveness through the standard approval process.
This distinction matters because it affects insurance coverage. Most private insurers and Medicare do not cover tests that lack FDA approval. TRICARE is a notable exception: the Defense Health Agency approved Galleri for annual screening in TRICARE patients aged 50 or older with a higher cancer risk, though coverage is limited to one test per lifetime and requires pre-authorization. For most people, the test is an out-of-pocket expense, typically around $949.
Where the FDA Application Stands
The FDA granted Galleri a Breakthrough Device designation back in 2018. This designation doesn’t authorize a test for sale. It signals that the FDA recognizes the technology’s potential and will work more closely with the company during development, with the goal of a faster review once the application is submitted. The standard of evidence required for approval stays the same.
GRAIL submitted its PMA application in modules, completing the final piece in January 2026. PMA is the most rigorous type of FDA review, typically reserved for high-risk medical devices and novel diagnostics. The FDA generally has 180 days to review a PMA application, though the process often takes longer with requests for additional data, advisory panel meetings, and back-and-forth between the agency and the applicant.
What the Test Does
Galleri is a blood test designed to detect signals from more than 50 types of cancer, many of which have no routine screening today. It works by analyzing fragments of DNA shed by tumors into the bloodstream, looking for chemical modifications that differ between cancerous and normal cells. When it returns a positive result, it also predicts where in the body the cancer originated, which helps guide the diagnostic workup.
The test is intended as a complement to standard cancer screenings like mammograms and colonoscopies, not a replacement. It targets cancers that currently lack screening options, such as pancreatic, liver, and ovarian cancers, which are often caught late.
How Accurate the Test Is
Galleri’s strongest feature is its low false positive rate. In the PATHFINDER II trial, specificity exceeded 99.5%, meaning fewer than 1 in 200 people without cancer received an incorrect positive result. That’s important for a screening test used in large populations, where even a small false positive rate can translate into thousands of unnecessary diagnostic procedures.
The flip side is sensitivity, particularly for early-stage cancers. Overall sensitivity for stage 1 and stage 2 cancers was 27.5%, meaning the test missed roughly three out of four early-stage cancers. When the analysis was narrowed to 12 cancer types the developers identified as having high unmet need (cancers with no standard screening), sensitivity improved to 52.8%. Sensitivity is substantially higher for late-stage cancers, but catching cancer early is the primary goal of screening.
When the test does return a positive result, the probability that cancer is actually present (the positive predictive value) falls between 55% and 68%, depending on the population studied. In practical terms, about 4 in 10 people who get a positive Galleri result will not have cancer confirmed on follow-up testing. That’s a meaningful rate of false alarms, though it compares favorably to some established screening tests like mammography.
What FDA Approval Would Change
If the FDA grants PMA, several things shift. Insurance coverage becomes far more likely. Medicare, in particular, typically requires FDA approval before covering a diagnostic test, and private insurers tend to follow. Broader coverage would dramatically expand access, since the current out-of-pocket cost is a barrier for many people.
FDA approval would also mean the agency has independently reviewed the clinical evidence and determined that the test’s benefits outweigh its risks for the intended population. Right now, the performance data comes from GRAIL’s own studies and independent academic analyses, but it hasn’t been through the formal regulatory filter that physicians and patients often rely on as a benchmark of credibility.
There is also a legislative angle. Several bills have been introduced in Congress to create a Medicare coverage pathway for multi-cancer detection tests, but progress on these has been tied in part to the FDA approval timeline. An approved test would likely accelerate coverage decisions across the board.
What This Means If You’re Considering the Test
You can order Galleri today through a healthcare provider, but you should understand what you’re getting. The test is best suited as an additional layer of screening on top of the standard tests recommended for your age and risk profile. It is not a substitute for colonoscopies, mammograms, cervical cancer screening, or lung cancer CT scans if you qualify for those.
A negative result does not mean you are cancer-free. Given the test’s modest sensitivity for early-stage disease, a clean result should not change your approach to standard screening. A positive result will require follow-up imaging and possibly biopsies to confirm whether cancer is present and where it is located. Roughly 4 in 10 positive results turn out to be false positives, so a positive Galleri result is a reason for further investigation, not a diagnosis.
If cost is a concern, the roughly $949 price tag is unlikely to be reimbursed by most insurers until FDA approval is granted. TRICARE beneficiaries aged 50 and older may be eligible for coverage but should confirm pre-authorization requirements with their provider first.